The biotech company said the FDA won't review its flu vaccine, in the latest hit to mRNA development As COVID-19 vaccine sales dwindle, pressure on Moderna to grow its business has increased.

WASHINGTON (AP) — The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday ...

The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...

Moderna’s mRNA-centric business is in conflict with the U.S. government’s shifting views on mRNA technology, and analysts say that’s a risk. The biotech announced Tuesday evening that in a rare move, ...